Background: Whether circadian rhythm disruption (CRD) promotes fibrotic remodeling after septic lung injury remains unclear. We tested whether CRD drives this process through macrophage CLOCK–PIEZO1 signaling. Methods: Lung specimens from patients with sepsis-associated lung injury and non-injured controls were analyzed alongside public murine lung transcriptomic datasets. Mice underwent cecal ligation and puncture or sham surgery and were maintained under stable or repeatedly shifted light–dark cycles; selected experiments included LysM-lineage Piezo1 deletion. Day-3 lung injury and day-28 fibrosis were assessed, and mechanisms were defined using genetic, biochemical and co-culture approaches. Results: CRD suppressed CLOCK expression in macrophage-lineage cells, leading to increased PIEZO1 expression and aggravated collagen deposition. CLOCK repressed Piezo1 transcription through a promoter E-box. Loss of myeloid Clock reduced Clock mesor and amplitude by 66.3% and 90.3%, respectively, increased Piezo1 mesor by 54.0%, and produced genotype-by-rhythm interactions for both genes (P < 0.0001). PIEZO1 activation impaired lysosomal acid lipase (LAL)–dependent lipophagy and promoted ZDHHC19-mediated peptidylarginine deiminase 4 (PAD4) palmitoylation and extracellular-trap formation. LysM-lineage Piezo1 deletion attenuated fibrosis. PIEZO1 inhibition or DNase I reduced epithelial injury and fibroblast activation induced by extracellular DNA-rich macrophage signals. Conclusions: CRD promotes post-septic fibrosis through a CLOCK–PIEZO1-linked macrophage immunometabolic program, identifying PIEZO1, extracellular DNA-rich traps and impaired lipid clearance as candidate targets.
Xiaohua Wang, Aming Sang, Wei Wang, Yujia Liu, Zirui Zhao, Haoxiang Li, Xiaoqi Xiong, Jie Cai, Ming Xu, Xinyi Li
Duchenne muscular dystrophy (DMD) is a fatal genetic disorder characterized by skeletal muscle degeneration and cardiomyopathy. Effective cardiac therapies remain limited. This study investigated the therapeutic potential of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (EMPA) in the dystrophin-deficient DBA2/J-mdx mouse model of DMD. Male mice received control chow or EMPA-containing chow (~25mg/kg/day), and cardiac function was evaluated longitudinally using four-dimensional ultrasound imaging. EMPA did not alter left ventricular mass or volume but delayed the onset of systolic dysfunction, preserving ejection fraction (EF) for 12 weeks and maintaining significantly higher EF through 24 weeks. EMPA also attenuated progressive impairments in systolic and diastolic myocardial deformation. Functional preservation was accompanied by reduced cardiomyocyte hypertrophy and reduced expression of cardiac stress genes. EMPA increased mtDNA copy number, reduced mtDNA damage, preserved the mtDNA-encoded respiratory chain protein MT-CO1, and increased myocardial ATP content, supporting improved mitochondrial integrity and myocardial energetic capacity. In addition, EMPA induced transcriptional changes consistent with enhanced fatty acid and ketone metabolism. Systemically, EMPA improved growth trajectory, preserved relative lean mass, increased skeletal muscle torque, attenuated fiber-type remodeling, and did not adversely affect renal function. Together, these findings support SGLT2 inhibitors as a promising therapeutic strategy for DMD-associated cardiomyopathy.
Benjamin J. Zeidler, Connor Thomas, John P. Salvas, Areli Jannes S. Javier, Alyssa M. Richards, Linda A. Bean, Conner C. Earl, Akanksha Agrawal, Niharika Narra, Steven N. Kozakiewicz, Lifan Zeng, Carol A Witczak, Joshua R Huot, Il-Man Kim, Meena S. Madhur, Mark C. Kowala, Larry W. Markham, Craig J. Goergen, Steven S. Welc
Monocyte-derived DC therapies programmed for robust IL-12p70 production have been associated with favorable outcomes in cancer clinical trials. However, clinical responses remain inconsistent even under standardized protocols, and the cellular basis for this variability is unknown. We leveraged single-cell multiomics to characterize two widely used DC platforms, the high-IL-12p70-producing α-Type-1-polarized DC (αDC1) and the IL-12p70-deficient DC induced in the presence of PGE 2 (PGE2-DC), at baseline and following rhCD40L activation. DC generated from 7 healthy participants representing the spectrum of rhCD40L-induced IL-12p70 production were profiled by transcriptome analysis with 42-plex surface proteomics, multiplex ELISA, and ELISpot quantification of IL-12p70-producing cells. While αDC1 and PGE2-DC distinctly responded to rhCD40L, αDC1 alone comprised 3 transcriptionally and phenotypically distinct subpopulations in resting and stimulated states. Only a limited fraction of αDC1 coexpressed IL12A and IL12B (IL-12p70 producers), confirmed by ELISpot at the protein level. The distribution of αDC1 subclusters varied markedly between individuals and correlated with bulk cytokine and chemokine secretion profiles. Magnetic enrichment on the surface marker CD116 yielded αDC1 fractions that differentially primed naïve CD4 + T cells, demonstrating these subpopulations are functionally divergent and separable. This heterogeneity may underlie inconsistent clinical outcomes, providing a rationale for subcluster-based release criteria and patient stratification.
Allison E. DePuyt, Peter E. J. Shoucair, Holly A. Bilben, Jeremy Martinson, Bernard J.C. Macatangay, Charles Rinaldo, Pawel Kalinski, Robbie B. Mailliard
The etiology of severe left-sided obstructive lesions (LSOL) of the heart, a common form of congenital heart disease (CHD), often remains unknown even after comprehensive genetic testing. Preclinical models implicate placental perturbations in abnormal cardiogenesis; however, little is known about connections between human placenta and fetal cardiac diseases. We profiled term placentas from severe LSOL pregnancies (n = 20) with and without placental pathologies and healthy controls (n = 10) to test whether severe fetal LSOL is associated with distinct transcriptomic and cellular states. Bulk RNA-sequencing of archival formalin-fixed paraffin-embedded tissues identified 1,030 differentially expressed protein-coding genes (580 [up], 450 [down]). Upregulated programs involved heart-valve development, endothelial signaling, and extracellular-matrix processes; while endocrine, trophoblast and gamma-aminobutyric acid signaling processes were downregulated. Severe LSOL pregnancies with histologically normal placentas showed enrichment of lymphatic-vascular development and cyclic-nucleotide signaling. Digital deconvolution analysis inferred reduced trophoblast fractions with reciprocal increase in endothelial and immune cell types. These findings support a unique placental gene expression in abnormal cardiac development, even in the absence of overt placental histopathology. These RNA expression signatures may serve as candidate biomarkers and lay the groundwork for mechanistic studies of the heart-placenta axis and future risk stratification in pregnancies with fetuses diagnosed with severe LSOL.
Rachel L. Leon, Huan Lu, Maria M. Ossa Galvis, Imran N. Mir, Bowen Xiong, Tao Wang, Durga Udayakumar
Adoptive T-cell therapies using tumour-specific T-cell receptors (TCRs) are limited by competition with endogenous receptors, impairing efficacy and posing risks of off-target autoreactivity. Here we present a CRISPR-based platform that selectively eliminates both endogenous TCR-α and -β chains without affecting transgenic TCRs, irrespective of codon optimization. This approach achieves >90% deletion efficiency in Jurkat and primary human T cells, enhancing expression and functional potency of transgenic receptors. Using an HLA-A*02:01-restricted DMF5 TCR, we show that dual TCR ablation boosts antigen-specific activation and cytotoxicity in vitro and enhances tumor clearance in vivo in human immune system (HIS) mice and prevents graft-versus-host disease (GVHD). Targeted locus amplification showed that CRISPR-induced double-strand breaks did not alter lentiviral integration profiles, supporting genomic safety. Extending this approach to four insulin-reactive TCRs demonstrated that endogenous receptor removal increased transduction efficiency and functional activity, with one (1E6) showing selective activation and infiltration of islet grafts (SC-islets) in vivo. This study establishes a universal, safe, and scalable genome-editing platform for generating functionally precise human T cells. By integrating cancer immunotherapy and autoimmune disease modelling within a single framework, it provides a preclinical rationale for dual endogenous TCR removal to improve specificity, safety, and therapeutic efficacy in TCR-based cell therapies.
Giorgia Zanetti, Sameena Nikhat, Mateusz Legut, Austin Chen, Farshid Fathi, Nathan Suek, Nato Teteloshvili, Hao Wei Li, Xiaolan Ding, Daniel Traum, Klaus H. Kaestner, Ryan E. Hoang, Andrew K. Sewell, Audrey V. Parent, Remi J. Creusot, Megan Sykes, Mohsen Khosravi-Maharlooei
TGF-β-activating integrins promote solid-organ fibrosis, suggesting their potential as disease markers. Chronic lung allograft dysfunction (CLAD), a progressive fibrotic complication that limits lung transplant survival, is driven by intragraft TGF-β activation. However, TGF-β-activating integrin expression patterns remain undefined in lung transplants. Single-cell RNA sequencing and proteomic analysis of tissue specimens from a mouse CLAD model and human explanted lungs with CLAD revealed high levels of the TGF-β-activating integrin αvβ6, primarily localized to fibrosis-associated Keratin 8+ alveolar transitional epithelial cells, which were greatly reduced in tolerant lungs. Molecular imaging with a newly optimized positron emission tomography radiotracer specific for αvβ6, [64Cu]Cu-DOTA-A20-K16R, showed significantly higher uptake in CLAD than in tolerant transplants. [64Cu]Cu-DOTA-A20-K16R activity was also reduced by experimental treatments that lowered αvβ6 expression and inhibited CLAD severity. Finally, [64Cu]Cu-DOTA-A20-K16R autoradiographic analysis of human explanted lungs with CLAD showed elevated activity that correlated with increased αvβ6 expression. Collectively, these findings illustrate the potential utility of αvβ6 molecular imaging for detecting CLAD pathogenesis.
Marlene Cano, Chandra S. Bathula, Fuyi Liao, Cristian Wieczorek Villas Boas, Yan Tao, Zhiyi Liu, Ricky Ebenezer, Victoria Davis, Allison Cannady, Dequan Zhou, Shunning Liang, Hanqiu Zhao, Derek E. Byers, Alexander S. Krupnick, Daniel Kreisel, Susan M. Lin, Allen Duong, Tereza Martinu, Zhiyu Dai, Buck E. Rogers, Andrew E. Gelman
Inflammatory bowel diseases (IBD) including Crohn’s disease (CD) are characterized by impaired intestinal epithelial barrier (IEB) function. Alterations in the desmosomal cadherin desmoglein 2 (Dsg2) have been linked to loss of IEB and intestinal inflammation in IBD. We investigated the pathogenic impact of a cytoplasmatic-truncating mutation in the desmosomal cadherin desmoglein 2 gene (DSG2) in an IBD patient. Genetic analysis of a CD patient revealed a likely pathogenic DSG2 mutation leading to a truncated protein lacking part of the intracellular domain. Generation of an enterocyte-specific mouse model to recapitulate the human mutation resulted in a lethal intestinal barrier defect which was evident in homozygous but not in heterozygous mice. In vitro, barrier defects correlated with changes in Dsg2 mobility and upregulation of pore-forming tight junction protein claudin-2. Organoids derived from heterozygous Dsg2 truncated mice exhibited increased epithelial susceptibility to proinflammatory cytokines. Bulk RNAseq followed by gene ontology analysis in homozygous mice revealed a skewed IL17/IL23 response overlapping with transcriptional changes in patients with CD. Furthermore, 16S rRNA sequencing revealed alterations in microbiome composition in animals that carried the Dsg2 truncation. In summary, a patient-derived mutation in the DSG2 gene causing cytoplasmic truncation in homozygous state induced a lethal intestinal barrier breakdown in mice paralleled by altered gut microbiota and intestinal immune response.
Daniela Kugelmann, Alexander García-Ponce, Nadja Thielemann, Mariya Y. Radeva, Maresa Anders, Da Eun Kang, Christian Siadjeu, Natalie Burkard, Anja K.E. Horn, Jessica Neubauer, Matthias Hiermaier, Desalegn T. Egu, Christoph Schmitz, Oliver Kurzai, Katri S. Vuopala, Outi Kuismin, Nicolas Schlegel, Jens Waschke
Essential thrombocythemia (ET) and myelofibrosis (MF) are myeloproliferative neoplasms (MPN) that can result from heterozygous or homozygous mutations in the calreticulin (CRT) gene (CALR). Mutant CRT binds to the thrombopoietin receptor to induce signaling that drives ET and MF. CRT is also a chaperone for the assembly of the highly polymorphic human leukocyte antigen (HLA) class I molecules. The effects of heterozygous versus homozygous MPN CALR mutations on the expression of HLA class I variants are unknown. To assess mutant CRT-induced changes to HLA class I expression, we generated CRISPR-based mutant CALR knock-in cell lines and CALR-knockout cell lines reconstituted with wild-type or MPN mutant CALR and also undertook measurements in MPN patient platelets and monocytes. Collectively, our findings indicate that heterozygous CALR mutations preserve HLA class I surface expression, whereas full loss of wild-type CRT results in marked, allele-dependent reductions in HLA class I expression, which are rescued by wild-type CRT but not MPN mutants. Reduced expression of CRT-dependent HLA class I in cells lacking a functional CRT induces natural killer (NK) cell activation. These studies identify specific HLA class I alleles and homozygous CALR mutations as prerequisites for low HLA class I expression in MPN.
Amanpreet Kaur, Grace Pagnucco, Fawziyah S. Khatri, Harini Desikan, Malathi Kandarpa, Matthew Cusick, Moshe Talpaz, Malini Raghavan
Osteoarthritis (OA) is a heterogeneous disease in which synovial inflammation drives structural progression and pain, yet the molecular diversity of synovitis remains poorly defined. Here, we performed a multimodal characterization of synovial tissues from 48 dogs with naturally occurring OA, integrating histopathology, immunohistochemistry, transcriptomics, MRI, and soluble mediator profiling. This analysis identified three discrete synovial pathotypes, pauci-immune, diffuse myeloid, and lympho-myeloid, defined by distinct immune cell composition and transcriptional programs reflecting biologically distinct endotypes. The lympho-myeloid pathotype, characterized by ectopic lymphoid structures and adaptive immune enrichment, was independently associated with greater structural joint damage on MRI despite comparable clinical scores, demonstrating that tissue stratification captures heterogeneity invisible to clinical assessment alone. Composite soluble mediator signatures correlated with disease severity across pathotypes. Cross-species analyses integrating a large human synovial cohort revealed conserved pathotype architecture and shared gene networks, including tyrosine kinase signaling and B cell receptor activation, validating the translational relevance of the canine model. Together, these findings provide a framework for patient stratification and therapeutic target discovery in OA, with broad implications for precision medicine within a One Medicine perspective.
Anaëlle Drieu-Vincent, Julien De Lima, Floriane M. Etienne, Romain Guiho, Noémie Podevin, Richard Danger, Florence Lezin, Nicolas Gaigeard, Sophie Allain, Jérôme Abadie, Thomas Rousseau, Pierre Maitre, Olivier Gauthier, Jérôme Guicheux, Marion S. Fusellier, Marie-Astrid Boutet
Alveolar microcysts, a hallmark of Idiopathic Pulmonary Fibrosis (IPF), are basal cell (BC)-lined structures that develop near terminal airways and correlate with poor clinical outcomes. Using primary-cell organoids and spatial transcriptomics, we identified striking epithelial similarities between respiratory bronchioles (RBs) and IPF alveolar microcysts, both containing AT0 (ABCA3+/SCGB3A2+), SCGB3A2+, and basaloid/BC populations, although basaloid/BCs were markedly expanded in IPF microcysts. A CEACAM6+ subset of normal RB epithelial cells, termed respiratory airway secretory cells (RASCs), consisted predominantly of SCGB3A2+ cells with only rare BCs (1–5%) that by RNA trajectory analysis suggested BCs arise from SCGB3A2+ progenitors. Accordingly, in organoid cultures nearly all RASC-derived colonies converted to BCs within 9 days, resembling colonies generated by purified BCs. BCs derived from either RASCs or normal alveolar type II (AT2) cells strongly expressed the collagenase matrix metalloproteinase-1 (MMP1), recapitulating the phenotype of BCs lining IPF microcysts. MMP1high BCs degraded type I collagen ex vivo and generated microcyst-like structures in vivo following xenotransplantation, both abolished by MMP activity inhibition or specific MMP1 deletion by sh-RNAi. Finally, a Frizzled-5 WNT agonist antibody reversed the MMP1high phenotype, identifying AT2- and RB-derived basal cell transdifferentiation as a previously unrecognized driver of alveolar destruction and microcyst formation in IPF and a potential therapeutic target.
Marylene Toigo, Kiana Garakani, Alexis N. Brumwell, Ying Wei, Tsung Che Ho, Paul J. Wolters, Michael A. Matthay, Stefano A. Iantorno, Vincent C. Auyeung, Harold A. Chapman, Claude Jourdan Le Saux
No posts were found with this tag.